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DERMATOFIBROSARCOMA PROTUBERANS: SURGICAL EXCISION VERSUS
MOHS SURGERY. Connie Chung, Mariel Eliza, Sumaira Aasi, David Leffell, and
Deepak Narayan. Section of Plastic Surgery and Section of Dermatologic Surgery and
Cutaneous Oncology, Department of Surgery and Department of Dermatology, Yale
University, School of Medicine, New Haven, CT.
The purpose of this project was to compare the recurrence rates of dermatofibrsarcoma
protuberans (DFSP) treated with surgical excision (SE) and Mohs surgery (MS) at Yale.
Patients were identified through the dermatopathology laboratory database and stratified
by treatment. The following information was collected: age at onset, sex, disease state
(primary presentation versus recurrence), tumor site, preoperative tumor size,
postoperative defect size, excisional margin, duration of follow-up, and recurrence after
treatment. Of the 30 patients, 14 were in the SE group, and 16 were in the MS group.
There were no recurrences in the SE group, and there was 1 recurrence (6%) in the MS
group, which occurred 37 months post-operatively. The average area of the tumors were
12.1 cm2 ± 16.1 (SE) and 5.3 cm2 ± 5.9 (MS), and the mean excisional margins were 3.8
cm ± 1.6 (SE) and 1.4 cm ± 0.5 (MS). The mean duration of follow-up in the SE group
was 33 months ± 41 (range: 1-116 months), and the mean duration of follow-up in the
MS group was 26 months ± 25 (range: 2 to 69 months.) Although the MS group had a
higher recurrence rate than the SE group, using the recurrence rates to make meaningful
conclusions about the efficacy of the two treatment modalities is limited by the small n,
lack of randomization to either procedure, and duration of follow-up. Once these issues
are addressed, recurrence rates must also be adjusted for patient and tumor characteristics,
that are associated with higher recurrence rates.
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Introduction
Dermatofibrosarcoma protuberans (DFSP) is a malignant soft tissue neoplasm
initially described in 1890 by Taylor, who wrote of a cutaneous tumor that looked like a
keloid and had the potential to recur. (1) More than 30 years later in 1924, Darier and
Ferrand further characterized this clinical entity and named it “progressive and recurrent
dermatofibroma.” (2) In the following year, Hoffmann coined the term
“dermatofibrosarcoma protuberans.” (3) Today, DFSP remains a distinct entity marked
by a triad of characteristics: its rarity, its slow growth, and its infiltrative nature.
On the whole, malignant soft tissue tumors are relatively rarer than carcinomas
and other tumors, so they account for only 0.8% to 1% of all cancers diagnosed each year.
(4) Therefore, it is very difficult to determine the frequency and incidence of DFSP, and
there are only a few large series that report the experience of a single institution over a
period of time. The earliest attempt found in the literature was in 1948 by Pack and
Tabah, who had 39 cases in 50,000 patients admitted to their mixed tumor service over
29 years. (5) They calculated a frequency of DFSP of less than 0.1% of all tumors and an
incidence of about 2 cases of DFSP a year. In 1967, McPeak, Cruz, and Nicastri added
86 more patients to this same service, and they attributed the threefold increase in
incidence to a rise in the total number of patients seen, as well as to improved recognition
of the distinct features of DFSP. (6)
More recently in the eighties, Bendix-Hansen and his group had 16 cases in 261
patients with soft tissue sarcomas over 16 years, and they calculated a frequency of DFSP

of 7% of all soft tissue sarcomas and an incidence of 0.8 cases of DFSP per one million
persons per year. (7) Finally, Chang et al. had 60 cases of DFSP treated between 1968
and 2001, compared to approximately 100 patients with any type of soft tissue sarcoma
who were treated each year at their institution (University of Illinois-Chicago), and
therefore, DFSP accounted for approximately 1.8% of all soft tissue sarcomas
encountered. (8)
Although the appearance of DFSP varies with the stage of the disease, DFSP
initially presents as a slightly raised sclerotic plaque-like mass or small nipple-like
projection on the surface of previously healthy skin, area of repeated trauma, vaccination
site, irradiated skin, or scar. (9) While firmly fixed to the overlying skin, DFSP is not
attached to the underlying deeper structures, but there may be multiple satellite nodules at
the periphery of the main lesion as well. (10) Pressure on the surface of the lesion causes
blanching (6), and the tumor is usually skin-colored with a brown-yellow or red tinge. (11)
(Figure 1) Occasionally, this discoloration precedes the development of a definite
tumefaction. (12) Therefore, this type of presentation can be misinterpreted as a keloid.
(13) Additionally, DFSP has been compared clinically with a morphea-type of basal cell
carcinoma and scleroderma. (4)
DFSP lesions typically arise on the trunk of the body, and in a series of 853
patients, the authors observed the following site distribution: trunk, 47%; lower extremity,
20%; upper extremity, 18%; and head and neck, 14%. (4) Moreover, DFSP is slightly
more common in men than in women, and in a series of 264 patients, the authors

Figure 1: An indurated plaque with firm, irregular nodules varying in color from flesh to reddish brown.

observed a male-to-female ratio of approximately 3:2. (14) Known to arise in patients of
widely varying ages, DFSP has an age distribution in the literature that ranges from six to
87 years of age, but the majority of patients present during early- to mid- adult life. (15)
There are a few reports citing lesions that presented in children, and there are 5 reported
cases of DFSP being present since birth. (1, 5, 16)
DFSP is characteristically slow growing, resulting in a long latency period and
lesions that persist for years without symptoms. (10) Therefore, in 3 earlier series, the
majority of patients did not seek medical care for at least 3 years. (6, 12, 17) However, in
2 more current series, the delay was usually less than 3 years. (7, 18) Eventually, DFSP
enters a rapid growth phase, producing pain or tenderness that usually prompts patients to
seek medical evaluation of the lesion. (10) As the rapidly growing mass enlarges, the

overlying skin stretches and thins, which can lead to ulcerations and bleeding, and the
lesion becomes fixed to the deep subcutaneous structures and fascial planes. (10)
Moreover, the satellite nodules at the periphery of the lesion coalesce into a larger mass
to obtain its typical “protuberant” appearance. (10) Although areas of extremely large
and neglected tumors may infarct and undergo spontaneous involution, deeper areas will
continue to grow and invade the surrounding tissue. (10) However, despite the enormous
size of some DFSP tumors, patients may appear well and without the signs of cachexia
that are commonly associated with other advanced cancers. (4)
The size of DFSP lesions at presentation, then, varies widely. In a series of 159
patients treated between 1950 and 1998, the authors found that the majority of lesions
were <5 cm in maximum diameter, but the lesion sizes had the following distribution:
<5cm, 134 patients (84%); 5-10 cm, 21 patients (13%); and >10 cm, 4 patients (3%). (15)
Of note, the authors found that the DFSP lesions were predominantly superficial; 121
patients (77%) had superficial lesions and 36 patients (22%) had lesions that had invaded
deeper structures. The depth of invasion was not reported in the remaining 2 patients
(1%).
Biopsies of DFSP reveal gray-white, rubbery, fibrous tissue that makes up a
solitary, multinodular, protuberant mass, and it is important to note that the mass appears
deceptively well–circumscribed, because DFSP is characterized by an infiltrative growth
pattern, and multiple finger-like projections can extend microscopically beyond the
visible margins. (10) In 1962, Taylor and Helwig meticulously described the

microscopic features of DFSP with a series of 115 cases, and histologically, the central
cellular portion of DFSP appears as a uniform population of atypical spindle-shaped cells
that show little pleomorphism or mitotic activity. (17) They observed that these cells
organize themselves radially around the vasculature in a distinct, but monotonous,
storiform or cartwheel pattern. (Figure 2)

Figure 2: Cells radiate from a central hub of fibrous tissue forming a cartwheel or storiform pattern.

During the initial period of slow growth, DFSP grows laterally along the
interfascicular spaces of the reticular dermis, so at the leading edge of the tumor,
attenuated malignant cells blend imperceptibly with dermal fibroblasts, making the
interface between tumor and normal tissue difficult to distinguish. (10) As the lesion

progresses, the tumor cells infiltrate the subcutaneous fat in an intricate, asymmetrical
pattern, resulting in a honeycomb pattern of entrapped fat cells. (10) (Figure 3) Vertical

Figure 3: DFSP extension into the subcutaneous fat results in a lacy or honeycomb pattern.

infiltration occurs during the period of rapid growth, resulting in ulceration as DFSP
spreads from the epidermis along the fascial planes of skeletal muscle. (10) However,
there are several unusual histological variants (Table 1), and the differential contains
more than 10 diagnostic considerations (Table 2). (11)

Table 1: DFSP variants

Table 2: Differential Diagnosis for DFSP

-Atropic DFSP
(morphea-like plaques)
-DFSP with giant cell angiofibroma
-Fibrosarcomatous DFSP
(sarcomatous areas)
-Myxoid DFSP
-Palisaded DFSP
(reminiscent of schwannoma)
-Pigmented DFSP
(Bednar tumor)
-Sclerosing DFSP
(abundant sclerotic tissue)

-Atypical fibroxanthoma
-Classic fibrosarcoma
-Fasciitis
-Myxofibrosarcoma
-Myxoid luposarcoma
-Cellular fibrous histiocytoma
-CD34+ benign fibrous hystiocytoma
-Dermal dendrocytic hamartoma
-Dermatomyofibroma
-Desmoplastic melanoma
-Neurofibroma
-Plexiform fibrohistiocytic tumor

It is important to note that regional and distant metastasis are rare despite the
aggressive local invasiveness of DFSP. In the early literature, the true incidence of
metastases is difficult to assess because of the inclusion of other spindle cell tumors. (10)
However, a recent study that used stricter criteria found that the risk for development of
metastatic disease is approximately 5%. (14) In this series of 913 cases of DFSP, 11
patients, or 1%, had regional lymph node metastasis, and 37 patients, or 4%, had distant
metastasis. Moreover, the overwhelming majority of reported metastases of DFSP follow
multiple local recurrences, and of these metastases, approximately 75% are
hematogenous spread to the lungs, with the remaining 25% being lymphatic spread to the
regional lymph nodes. (4) Rare metastases to the brain, bone, and heart have also been
documented. (4) Increased cellularity and mitotic activity are important factors in
enhancing the metastatic potential of DFSP. (19)
Differentiation of DFSP, therefore, is aided by immunostaining with CD34 and
Factor XIIIa. CD34 is a 110-kD glycosylated transmembrane protein of unknown
function that is raised against the human myeloid leukemia cell line KG1a. (20) In

addition to being identified on vascular endothelial cells, their derivative tumors, and
dendritic interstitial cells within the gastrointestinal tract (21, 22), CD34 has also been
identified in 10 to 30% of the dendritic interstitial cells in the reticular dermis, as well as
in spindle cells in and around the eccrine glands, and perifollicular spindle cells in the
midportion of the hair follicle. (23) However, dendritic interstitial cells in the upper
papillary dermis, which are cytologically similar to those found in the reticular dermis,
are immunophenotypically distinct, so they are CD34 negative but factor XIIIa positive.
(24) Factor XIIIa is a tetrameric protein also known as fibrin-stabilizing factor and plays
a key role in the coagulation system. (25) While DFSP stains positively for CD34 and
negatively for factor XIIIa, dermatofibromas, or benign fibrous histiocytomas, stain
negatively for CD34 and positively for factor XIIIa. (26) This distinction is particularly
clinically relevant in terms of treatment.
Three other novel markers can also help distinguish DFSP lesions from
dermatofibromas. Dermatofibromas tend to stain positively for CD44, a membrane
glycoprotein thought to be the cell surface receptor for hyaluronate, the major component
of the extracellular matrix, while DFSPs tend to have absent or significantly reduced
CD44 immunostaining. (27) Another marker than can help distinguish between DFSP
lesions and dermatofibromas is p75, a low-affinity nerve growth factor receptor. (28) A
wide variety of mesenchymal and epithelial tumors stain positively for p75, indicating
that p75 expression is not specific to nerve sheath tumors, but in one study, DFSP lesions
stained positively of p75 in 69 of 73 DFSP lesions, or 95% of the lesions, while

dermatofibromas had negative immunostaining for p75. (28) Finally, Apo D, which is a
33kDa glycoprotein that acts as a component of the high density lipoprotein structure,
demonstrated strong immunoreactivity in 9 of 10 typical DFSP lesions in a study, as well
as in 5 of 6 DFSP variants, while immunostains were negative in 16 of 16
dermatofibromas, as well as in 12 of 12 dermatofibroma variants. (29)
Although thought to arise from a dermal stem cell or an undifferentiated
mesenchymal cell with fibroblastic, muscular, and neurologic features, the pathogenesis
of DFSP is not fully understood. (30) However, Japanese researchers in 2002
demonstrated that chromosomal translocations or ring chromosomes occur in DFSP
through a fusion of chromosome regions 17q22 and 22q13. (31) These gene locations
code the alpha chain of type I collagen (COL1A1) and the beta chain of platelet-derived
growth factors (PDGFβ), and the same abnormality is found in giant cell fibromas. (32)
As a result, there is deregulation of PDGFβ chain expression, because the ring
chromosome expresses a COL1A1-PDGFβ fusion protein that binds to the PDGF
receptor β protein tyrosine kinase, leading to constant activation and stimulation for
growth of DFSP cells. (33, 34)
The extent of deep invasion of DFSP can be evaluated with magnetic resonance
imaging (MRI), and Torreggiani et al. applied this technique in a series of patients with
large recurrent DFSP lesions. (35) In their study, 10 patients with DFSP underwent MRI,
and conventional T1-weighted images revealed the DFSP lesion to be isointense
compared with skeletal muscle in 5 of the patients, slightly hypointense in 3 of the

patients, and hyperintense in the remaining 2 patients. Of note, all of the DFSP lesions
were hypointense compared with the subcutaneous fat. However, when conventional T2weighted images were obtained in 6 of the patients, and fast spin-echo T2-weighted
images were obtained in the remaining 4 patients, half of the patients had DFSP lesions
that had a higher signal intensity than that of subcutaneous fat, and half of the patients
had DFSP lesions that had a similar signal intensity than that of subcutaneous fat. On the
other hand, computed tomography (CT) is not indicated as an initial diagnostic modality
for DFSP lesions, except in rare cases in which one suspects underlying bone
involvement. (8) Although DFSP rarely exhibits lymphatic or hematogenous
dissemination, the occasional patient with advanced, recurrent, and/or intermediate grade
DFSP lesions may have pulmonary metastases, and therefore, it is recommended that
these patients receive a chest x-ray. (8)
Although the American Joint Committee on Cancer has not set forth a system
specific for the staging of DFSP, it is currently staged in accordance with the American
Musculoskeletal Tumor Society (MSTS) staging system, which takes into account tumor
grade and compartmentalization. MSTS Stage 1A DFSP tumors are low-grade lesions
without extension beyond the subcutaneous compartment, and Stage 1B DFSP tumors are
low-grade lesions with extracompartmental extension into the underlying fascia or
muscle. (36, 37)
While it is clear that the optimal treatment for DFSP is resection, the literature
remains unclear about the optimal mode of resection, and patients may be treated by wide

surgical excision or Mohs micrographic surgery. In both procedures, the characteristic
finger-like extensions of DFSP that lie beneath clinically normal appearing skin makes
complete removal difficult, and recurrence rates of DFSP for both wide local surgical
excision and Mohs micrographic surgery vary widely from study to study.
In wide surgical excision, clinically evident tumor is excised with a rim of normal
appearing tissue. This additional margin is removed because the characteristic
microscopic extensions of DFSP cannot be visualized or palpated by the surgeon.
Therefore, specimens are subsequently evaluated by pathologists. Standard frozen
sections are usually cut vertically, as in slicing a loaf of bread, measuring approximately
10 millimicrons (mu) in thickness, and representative vertical sections are examined in
each of the 4 quadrants of the specimen (ie. 12, 3, 6, and 9 o’clock positions). (38) If the
viewed sections do not show tumor, the margins are called clear. Although other
unexamined slices may still contain tumor, it is impractical to examine all of the vertical
sections of a specimen; for example, a 5mm long piece of tissue would necessitate the
preparation and examination of 5000 individual specimens. Ultimately, less than 1% of
the interface between the specimen and the patient is actually examined histologically
(39), so standard vertical step sectioning may miss microscopic DFSP. However, tumor
recurrence is not correlated with tumor size, but correlated instead with resection margins
of the tumor. (40) In a study of 48 patients with DFSP, the authors found a trend toward
decreasing recurrence with increasing excision margins; while there was a 41%
recurrence rate with margins less than 2 cm, there was a 24% recurrence rate with

margins greater than or equal to 2 cm. (40) Currently, 3 cm margins are recommended in
a standard wide surgical excision. (38)
In Mohs micrographic surgery, the dermatologist is both surgeon and pathologist,
and the procedure couples serial excision with microscopic examination to trace the
tumor. Frederic E. Mohs originated this technique while working as a cancer research
assistant during medical school in the early 1930s, serendipitously observing preservation
of the microscopic detail of the tissue while testing the irritant effect of an intratumoral
injection of 20% zinc chloride. (41) His observation that the tissue appeared as though it
had been excised and immersed in a fixative solution gave birth to the idea of excising
tumors under microscopic control.
Currently, excision of a layer of the tumor is followed by evaluation of horizontal
frozen sections to determine deep tumor margins, allowing preservation of the maximal
amount of normal tissue. (42) The tissue layer is 1) divided into smaller specimens, 2)
numbered consecutively, 3) inked to distinguish left and right skin edges, and 4) mapped
to show the anatomic origin of each specimen. Frozen sections measuring 6-10 microns
in thickness are sliced from the bottom and sides of each specimen, stained, and
examined under the microscope by the dermatologist. Residual tumor is drawn on the
previously drawn map of the tissue layer, and the another tissue layer is removed. This
cyclic process of excision, mapping, and microscopic examination is repeated until no
residual tumor is found microscopically. (42) (Figure 4) Therefore, almost 100% of the
tumor margins are examined histologically. (39)

Figure 4: Mohs surgery is a cyclic process of excision, mapping, and microscopic examination. (39)

Statement of Purpose
The aim of this project was to compare the recurrence rates of DFSP treated with
surgical excision and Mohs surgery at Yale with the hypothesis that the recurrence rate of
DFSP treated with surgical excision would be lower than the recurrence rate of DFSP
treated with Mohs surgery.

Methods
Thirty patients were identified at the request of Drs. Aasi and Narayan by the
Yale dermatopathology laboratory database as those who had been treated at this
institution for DFSP from 1990, when the database was created, to 2005. Patients were
divided into two treatments groups according to whether they had undergone surgical
excision or Mohs surgery. Hospital and clinic charts were obtained by this author, who
collect the following information: age at onset, sex, disease state (primary presentation
versus recurrence), tumor site, preoperative and postoperative tumor size, excisional
margin, duration of follow-up, and recurrence after treatment. Attempts were not made
to contact patients when follow-up data was not available in their medical records.
The recurrence rate and average duration of follow-up were then calculated for
each of the treatment groups by this author. Although data on excisional margins were
available in the surgical excision group, data on excisional margins for the Mohs surgery
group was not similarly available. Therefore, excisional margins were calculated in the
following manner: the larger measurement of the preoperative tumor size was subtracted
from the larger measurement of the postoperative defect size to obtain a total margin.
This total margin was divided in half based on the assumption that the margin was
applied circumferentially around the lesion to yield the actual margin. The smaller
measurement of the preoperative tumor size was also subtracted from the smaller
measurement of the postoperative defect size and divided in half. These two values were
then averaged to arrive at the excisional margin for each patient.

Results
Patient characteristics
Of the 30 patients, 14 were in the surgical excision group, and 16 were in the Mohs
surgery group. The age range in the surgical excision group was 10 to 84 years, and the
mean age was 46 years ± 19. The age range in the Mohs surgery group was 11 to 46 years,
and the mean age was 38 years ± 12. The distribution of sex was similar in each group;
71% , or 10 out of 14 patients, were female in the surgical excision group, and 69%, or 11
out of 16 patients, were female in the Mohs surgery group. While none of the 30 patients
presented to Yale with local or distant metastasis, 3 patients presented with recurrent
DFSP. Of these 3 patients, 1 was in the surgical excision group, and 2 were in the Mohs
surgery group.
Tumor characteristics
In the surgical excision group, most of the DFSP lesions were on the trunk, and a
fifth of them were on the head or neck. More specifically, there were 4 patients with
lesions on the chest, 4 on the abdomen, and 3 on the back, totaling 11 out of 14 patients
(79%) with lesions on the trunk. The remaining 3 out of 14 patients (21%) in the surgical
excision group had lesions on the head or neck. (Figure 5) In the Mohs surgery group,
approximately half of the DFSP lesions (56%) were on the trunk, and a quarter of the
DFSP lesions were on the extremities. The remaining lesions were on the head or neck
(2 out of 16 patients) and the vulva (1 out of 16 patients). More specifically, there were 4
patients with DFSP lesions on the chest, 3 on the abdomen, and 2 on the back, totaling 9

out of 16 patients with lesions on the trunk. Of the 4 DFSP lesions on the extremities in
the Mohs surgery group, there were 3 lesions on the lower extremities and 1 lesion on the
upper extremity. (Figure 6) The average area of the tumor was larger in the surgical
excision group at 12.1 cm2 ± 16.1; the average area of the tumor in the Mohs surgery
group was 5.3 cm2 ± 5.9.
SE Group: Tumor Location

MS Group: Tumor Location

Extremities:
0, 0%
Other: 0, 0%
Head/Neck:
3, 21%

Other: 1, 6%

Head/Neck:
2, 13%

Extremities:
4, 25%

Trunk: 11, 79%

Trunk: 9,
56%

Figure 5: Distribution of tumor location
in the surgical excision group, n=14.

Figure 6: Distribution of tumor location
in the Mohs surgery group, n=16.

Surgical excision vs. Mohs surgery
Mohs surgery was performed on all 16 DFSP patients in the Mohs surgery group
by 1 dermatologist in the Section of Dermatologic Surgery and Cutaneous Oncology in
the Department of Dermatology at Yale. However, the 14 surgical excisions were carried
out by 3 surgeons in the Section of Plastic Surgery in the Department of Surgery at Yale,
as well as by the dermatologist previously mentioned. The three plastic surgeons
operated on 3 patients, 3 patients, and 5 patients respectively, and the dermatologist

performed the remaining 2 surgical excisions.
The initial mean excisional margin for the surgical excision group was 2.8 cm ±
0.4. However, 6 of the 14 patients in the surgical excision group had positive margins on
the final pathology report from their initial surgery, and they underwent a second surgical
excision by the same physician. (This second excision occurred within an average of 23
days ± 13.) When the excisional margins from the revision surgery were added to the
initial margins, the mean excisional margin for the surgical excision group became 3.8
cm ± 1.6. (The width of the additional margins were available in the operative notes.)
The mean excisional margin for the Mohs surgery group, however, was smaller at 1.4 cm
± 0.5, and no revision procedures were required. The mean duration of follow-up in the
surgical excision group was 33 months ± 41, and the range of follow-up was 1 to 116
months. One of the patients in this group did not return for follow-up after her surgery.
The mean duration of follow-up was shorter in the Mohs surgery group at 26 months ± 25,
and the range of follow-up was 2 to 69 months. Interestingly, one of the patients in this
group did not return for follow-up after her surgery as well. (Table 3)
Table 3: Summary of treatment data

Surgical Excision

Mohs Surgery

3.8 ± 1.6 cm

1.4 ± 0.5 cm

Follow-up

33 ± 41 months

26 ± 25 months

Recurrence

0/14, 0%

1/16, 6%

Margins

There was 1 recurrence in this series, and the patient was in the Mohs surgery
group. This patient initially presented to Yale with a recurrent tumor, and he developed
the recurrence 37 months after his Mohs surgery. The dermatologist removed the
recurrent tumor with surgical excision. Therefore, the recurrence rate for the Mohs
surgery group was 6% (1/16), and the recurrence rate for the surgical excision group was
0%.
Discussion
Dermatofibrosarcoma protuberans (DFSP) is a malignant soft tissue neoplasm
with three key characteristics: it is very rare, it is slow growing, and it grows by
asymmetric infiltration into deeper tissues. Although there is a consensus in the literature
that tumor excision is the most effective treatment of DFSP, there is currently no
consensus on which excisional technique is the most effective, because the microscopic
finger-like projections of DFSP are difficult to eradicate completely in either wide
surgical excision or Mohs micrographic surgery. Recurrence rates vary widely for both
procedures, and moreover, recommended resection margins vary widely for wide surgical
excisions.
Since the first studies in 1951, the literature currently contains over 30 series in
which DFSP was removed by surgical excision. (Table 4) The average recurrence rate
was 23% (range: 0% to 60%), and the total recurrence rate was 21% (334/1598). Given
the variable follow-up periods, which ranged from 1 month to 25 years when stated, as
well as variable numbers of patients, which ranged from 7 to 218, the large range of

recurrence rates is not surprising. Resection margins also ranged from “conservative” to
5 cm when they were defined, but the vast majority of studies used excisional margins
greater than or equal to 2 cm. However, tumor location can limit the width of margins in
surgical excision; generous excisional margins are not practical for DFSP on the face or
distal extremities. (38)
Table 4: Local recurrence rates after surgical excision of DFSP
Authors

Year

Pack, Tabah (5)
Gentele (43)
McGregor (44)
Taylor, Helwig (17)
Burkhardt, et al. (12)
McPeak, et al. (6)
Longhin (45)
Tamoney (46)
Hadju (47)
Bendix-Hansen, et al. (7)
Barnes, et al. (48)
Waldermann, Hagedorn (49)
Petoin, et al. (50)
Roses, et al. (40)
Chattopadhyay, et al. (51)
Rutgers, et al. (14)
Brabant, et al. (52)
Mark, et al. (53)
Koh, et al. (54)
Gloster, et al. (38)
Arnaud, et al. (55)
Gayner, et a. (56)
Sondak, et al. (57)
Lindner, et al. (37)
Stojadinovic, et al. (58)
Bowne, et al. (15)
D’Andrea, et al. (59)
Oliveira-Soares, et al. (60)
Vandeweyer, et al. (61)
Khatri, et al. (9)
Chang, et al. (8)
Dubay, et al. (62)
Fiore, et al. (63)
Behbahani (64)

1951
1951
1961
1962
1966
1967
1967
1971
1979
1983
1984
1985
1985
1986
1986
1992
1993
1993
1995
1996
1997
1997
1999
1999
2000
2000
2001
2001
2002
2003
2004
2004
2005
2005

Totals

N,
patients
39
38
7
98
21
82
44
12
119
18
15
13
96
48
10
19
14
15
19
39
107
32
45
35
33
159
14
13
18
24
60
40
218
34

N,
recurrences
8
16
0
48
7
8
14
3
64
8
8
3
6
16
6
8
0
9
5
5
2
11
0
20
3
34
1
2
1
0
10
0
8
0

Recurrence
rate, %
21
42
0
49
33
10
32
25
53
44
53
23
6
33
60
42
0
60
26
13
2
34
0
37
9
21
7
15
5.5
0
17
0
4
0

1598

334

21

Follow-up,
yrs
0.5-20
NS
1-6
1-17
>5
3-15
1-11
1-30
NS
5-13
1-23
1-7
1-15
>3
5-7
2-28
1-5
3-16
>3
0.8-14
NS
0.8-24
NS
1-12
NS
NS
2-8
0.16-17
NS
NS
1-25
NS
NS
NS

The use of Mohs surgery in the treatment of DFSP was first described in 1978 by

Mohs himself. (65) The literature currently contains at least 27 reports in which DFSP
was removed by Mohs surgery, but almost a third of these reports have only 1 or 2
patients in them. (Table 5) The average recurrence rate was 1.9% (range: 0% to 14%),
and the total recurrence rate was 2.7% (9/337). Therefore, recurrence rates for Mohs
surgery are lower than recurrence rates for surgical excision. However, patients with
surgical excision had a longer follow-up period, so patients with Mohs surgery may have
late recurrences. Also, Mohs surgery has several drawbacks that limit its widespread use
in the treatment of DFSP. (57) The Mohs surgeon requires considerable training, as well
as a specialized ancillary team, and the learning curve is steep. (57) Moreover, the
surgery itself is labor and time intensive, and since it is performed under local anesthesia,
large or bulky tumors are difficult to remove. (57)
Table 5: Local recurrence rates after Mohs surgery for DFSP
Authors

Year

Mohs (65)
Mikhail, Lynn (66)
Peters, et al. (67)
Hess, et al. (68)
Robinson (69)
Hobbs, Ratz (70)
Hobbs, et al. (71)
Weber, et al. (72)
Rockley, et al. (73)
Goldberg, Maso (74)
Parker, Zitelli (75)
Dawes, Hanke (76)
Gloster, et al. (38)
Barlow, et al. (77)
Kelley, et al. (78)
Garcia, et al. (79)
Ratner, et al. (80)
Haycox, et al. (81)
Hafner, et al. (82)
Huether, et al. (83)
Ah-Weng, et al. (84)
Nouri, et al. (85)

1978
1978
1982
1985
1985
1988
1988
1988
1989
1990
1995
1996
1996
1996
1996
1996
1997
1997
1999
2000
2002
2002

N,
patients
7
2
1
1
4
1
10
1
1
1
20
24
15
2
21
16
58
10
5
18
21
20

N,
recurrences
0
0
0
0
0
0
0
0
0
0
0
2
1
0
3
0
1
0
0
1
0
0

Recurrence
rate, %
0
0
0
0
0
0
0
0
0
0
0
8
7
0
14
0
2
0
0
5.5
0
0

Follow-up,
months
>60
>60
42
18
>60
25
15-91
6
18
12
3-105
NS
5-96
24-35
>60
NS
3-170
NS
NS
NS
21-80
4-216

Oliveira-Soares, et al. (60)
Tom, et al. (86)
Wacker, et al. (87)
DuBay, et al. (62)
Snow, et al. (42)
Totals

2002
2003
2004
2004
2004

7
9
22
11
29

1
0
0
0
0

14
0
0
0
0

337

9

2.7

NS
19-74
NS
NS
60-240

In this study, there was no recurrence in the surgical excision group, and there
was 1 recurrence in the Mohs surgery group, resulting in a 6% recurrence rate for Mohs
surgery and supporting the hypothesis that the recurrence rate of DFSP treated with
surgical excision would be lower than the recurrence rate of DFSP treated with Mohs
surgery. However, this conclusion must be considered in light of several key limitations
to this study.
First, this study had a small n since DFSP is a very rare disease; there were 14
patients in the surgical excision group and 16 patients in the Mohs surgery group.
Therefore, 1 or 2 recurrences can completely change the results of the study. Even 1
recurrence in the surgical excision group would lead to a 7% recurrence rate, and the rate
of recurrence in the surgical excision group would be higher than the rate of recurrence in
the Mohs surgery group.
Second, all of the patients in the study were referred to the dermatologist or
plastic surgeon by their primary care physicians, but they were not randomly assigned to
the 2 treatment groups. However, the patients were not assigned to the 2 treatment
groups by any identifiable criteria either. Therefore, one cannot completely compare
treatment outcomes, such as the recurrence rate, to conclude that one treatment modality
is more effective than the other is.
Third, even if all of the patients were randomly assigned to the 2 treatment groups,
comparing recurrence rates to evaluate the efficacy of surgical excision and Mohs surgery

also depends on the length of follow-up. More specifically, only recurrence rates at the
same time point can be meaningfully compared, and the latest time point at which
recurrence rates can be compared is equal to the shortest duration of follow-up among all
of the patients. In this study, the shortest duration of follow-up was only 1 month,
despite a mean duration of follow-up for all of the patients of 29 months, and there were
no recurrences in both the surgical excision and Mohs surgery groups at 1 month.
However, no other meaningful comparisons of recurrence rates can be made beyond this
time frame.
Finally, comparing recurrence rates for surgical excision and Mohs surgery
demands adjustment for key factors, such as patient and tumor characteristics, in a
multivariate analysis, because increased age, histologic subtype, high mitotic index,
cellularity, location on the head and neck, and recurrent lesions are associated with higher
recurrence rates. (15, 53, 56, 88) Most recurrences occur within 3 years of the primary
excision, and recurrent tumors tend to recur. (6, 17, 40, 48, 53) Investigators in Germany
specifically measured the subclinical spread of DFSP and found that, on average,
recurring tumors infiltrated twice as far beyond the clinically visible tumor margin (22.4
mm) as primary tumors (10.0 mm). (89)
There are 2 ways to overcome these limitations in order to compare the outcomes
of surgical excision and Mohs surgery in the treatment of DFSP. To increase the size of
the study, concurrent data could be pooled from other institutions, or this data could be
added to previous series listed in Tables 4 and 5, to make meaningful statistical analysis

possible. Moreover, this study would benefit greatly from contacting patients lost to
follow-up in order to compare recurrence rates of surgical excision and Mohs surgery
beyond 1 month.
However, while tumor resection remains the mainstay of treatment of DFSP,
radiation therapy (RT) has an adjuvant role. Although data assessing the efficacy of RT
alone in the treatment of macroscopic disease is currently limited, several studies have
concluded that RT administered before either before of after surgery significantly reduces
the risk of local recurrence in patients who have or who are likely to have close or
positive margins when wide excision would result in cosmetic or functional loss. (90, 91,
92, 93) In the most recent study in this series, 1 of the 10 patients (10%) who received
adjuvant RT after surgical resection developed a recurrence, and 9 of the 24 patients
(37.5%) who received only surgical resection developed a recurrence. (94) The
appropriate dose fractionation schedules and treatment techniques are similar to those
that are used for other soft tissue sarcomas. (95) Moreover, after reviewing a series of
studies evaluating the efficacy of RT, the authors conclude that despite the limited data,
RT alone is reasonably likely to result in cure for the occasional patient with unresectable
macroscopic disease. (96) However, the slow growth rate of DFSP precludes the use of
chemotherapy as an effective treatment modality, (10) but may be used in metastatic
disease. (49)
Finally, an additional adjuvant treatment option may be molecularly targeted
therapy against the fusion protein COL1A1-PDGFβ. As discussed above, this molecule

is found in DFSP tumors and stimulates tumor growth. Although originally approved for
the treatment of chronic myelogenic leukemia, imatinib/STI-571 (Gleevec), which is a
potent and specific inhibitor of several protein-tyrosine kinases, also interrupts the
continuous stimulation of the DFSP cells by inhibiting platelet-derived growth factor
receptors in vitro (34, 97) and in selected patients. (98) In 2003, the Task Force for
Dermatologic Oncology (ADO), together with the German Society for Dermatologic
Surgery and Oncology, initiated an open, multi-institutional phase II study to evaluate the
therapeutic efficacy of Gleevec in a larger patient population. (11)
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